Featured Post

Florida's Space Coast Faces Serious Flash-Flood Threat After Days of Heavy Rain

Florida's Space Coast Faces Serious Flash-Flood Threat After Days of Heavy Rain Parts of Florida's Atlantic coast faced a serious flash-flood threat on Friday, November 20, after repeated rounds of heavy rain affected communities along the Space Coast. The National Weather Service's Weather Prediction Center warned that additional rainfall could worsen flooding in areas where the ground was already saturated and rivers had risen significantly. The situation is particularly concerning because flooding can continue even after the heaviest rain has moved away. Water may accumulate in streets, drainage systems, creeks and rivers, creating hazards for residents, drivers and emergency responders. What the latest weather warnings say In its Friday morning storm summary, the Weather Prediction Center reported that catastrophic flash flooding was possible along Florida's Space Coast through Saturday. Flash Flood Warnings were in effect for parts of Volusia, Seminole and...

FDA Investigates Malignancy Reports Following Zolgensma Gene Therapy

FDA Investigates Malignancy Reports Following Zolgensma Gene Therapy

The US Food and Drug Administration is investigating reports of malignancies in patients who received Zolgensma, a gene therapy used to treat spinal muscular atrophy. The agency issued a MedWatch alert on November 6, 2026, after reviewing postmarketing adverse-event reports involving patients treated with the therapy.

The investigation highlights the importance of long-term safety monitoring for advanced medical treatments. Gene therapies can offer important treatment options, but their effects may require careful observation after approval and wider clinical use.


What the FDA Has Reported

The FDA said it had received reports of tumors in patients treated with Zolgensma. These reports included tumors involving the central and peripheral nervous systems, spinal and paraspinal regions, and kidneys.

The agency also identified three reported cases involving GLI1, a gene associated with cancer when it is abnormally activated or overexpressed. The FDA is investigating the possible relationship between the treatment and these reports.

Why Postmarketing Monitoring Matters

Clinical trials are designed to evaluate the safety and effectiveness of medical products, but they involve a limited number of participants and a defined observation period. After a treatment becomes available more widely, regulators can receive additional information from patients and healthcare professionals.

Postmarketing reports help identify potential safety signals that may not have been fully understood during earlier testing. A reported adverse event does not automatically establish that a medicine caused the condition, which is why regulators investigate patterns and biological explanations.

What Patients and Families Should Understand

This FDA alert is not a substitute for individualized medical advice. Patients and families affected by spinal muscular atrophy should discuss the agency's communication with their treating specialists, who can explain the relevance of the information to a particular treatment history.

They should not stop or change a prescribed treatment without speaking to the healthcare team responsible for their care.

How Regulators Evaluate New Safety Information

Regulatory investigations may involve reviewing case reports, examining biological mechanisms and assessing whether product labeling or other safety measures need to change.

The Zolgensma alert demonstrates why monitoring continues after a therapy reaches patients. Medical innovation and patient safety are connected responsibilities, and transparent communication helps clinicians and families make informed decisions.

Medical researcher examining laboratory samples in a clinical research facility

 

Comments

Popular posts from this blog

African Negotiators Challenge Wealthy Countries Over Climate Finance Promises at COP31